Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

View More »

Google Scholar citation report
Citations : 2051

Journal of Vaccines & Vaccination received 2051 citations as per Google Scholar report

Flyer image
Journal of Vaccines & Vaccination peer review process verified at publons
Flyer image
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
View More
Useful Links
Share This Page
Open Access Journals
View More
A clinical trial to evaluate the safety and immunogenicity of a novel DNA vaccine used in combination with meglumine antimoniate as immunotherapy during leishmaniasis
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Laura Manna

Accepted Abstracts: J Vaccines Vaccin

Abstract:

T wenty leishmaniotic dogs from a leishmaniasis-endemic area (Naples, Italy) were enrolled in a clinical trial and were randomly assigned to receive three consecutive subcutaneous injections of vaccine at 10-days intervals (n=10\20), saline placebo (n=10\20). All dogs received chemotherapy with meglumine antimoniate (100mg7kg\30days\sc) starting on day 0. The vaccine was safe and well tolerated. Leishmania DNA load, IFAT, INF- γ and IL4 mRNA expression levels were tested before and after the therapy, every 3 months for a period of 12 months. Analysis of the data indicated that the vaccine was safe and immunogenic in CVL dogs and appeared to shorten their time to cure when used in combination with meglumine antimoniate chemotherapy.

Biography :

Laura Manna has completed her PhD in the University of Naples on the 1998. Since 2005, she is a Researcher of Department of Veterinary Medicine and Animal Productions of University of Naples. Her research interest is to develop a protective vaccine for the prevention and treatment of leishmania sis. She has published many papers in international journals

PDF HTML